Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03879694
Recruitment Status : Recruiting
First Posted : March 19, 2019
Last Update Posted : June 21, 2019
Sponsor:
Collaborators:
NeuroEndocrine Tumor Research Foundation (NETRF)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute

Brief Summary:
This phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. The body sees these proteins as not belonging and sends white blood cells called T cells to attack the tumor cells that contain these proteins. By vaccinating with small pieces of these proteins called peptides, the immune system can be made to kill tumor cells. Giving survivin long peptide vaccine to patients who have survivin expression in their tumors may create an immune response in the blood that is directed against neuroendocrine tumors.

Condition or disease Intervention/treatment Phase
Lung Atypical Carcinoid Tumor Lung Typical Carcinoid Tumor Metastatic Pancreatic Neuroendocrine Tumor Biological: Incomplete Freund's Adjuvant Drug: Octreotide Acetate Biological: Sargramostim Biological: SVN53-67/M57-KLH Peptide Vaccine Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To assess safety, tolerability and toxicity of SVN53-67/M57-KLH peptide vaccine (SurVaxM) in emulsion with incomplete Freund's adjuvant (montanide ISA 51) and given subcutaneously with sargramostim (granulocyte macrophage-colony-stimulating factor [GM-CSF]) in combination with a somatostatin analogue, octreotide acetate (Sandostatin LAR) in patients with survivin positive metastatic neuroendocrine tumors (NETs).

SECONDARY OBJECTIVES:

I. To determine clinical benefit (including complete response, partial response and stable disease as defined by Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) at 6 months, 9 months and 12 months from study entry.

II. To evaluate the immunogenicity of SurVaxM in NETs by measuring anti-survivin antibody levels and anti-tumor T-cell responses in peripheral blood.

III. To determine time to progression (TTP) compared to prior to study entry, in patients with metastatic NETs treated with SurVaxM and octreotide who experienced progression on therapy with a somatostatin analogue.

EXPLORATORY OBJECTIVES:

I. To explore immune markers associated with clinical responses to SurVaxM in peripheral blood of NETs patients.

OUTLINE:

Patients receive a SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant subcutaneously (SC) and sargramostim SC on day 0. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Patients also receive octreotide acetate intramuscularly (IM) on day 0. Cycles of octreotide acetate repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain free of tumor progression at 6 months and do not develop any regimen-related toxicity or serious adverse events will be eligible to receive additional doses of the vaccine and sargramostim every 3 months, for up to 1 year from the start of treatment.

After completion of study treatment, patients are followed up for 3 months.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)
Actual Study Start Date : June 13, 2019
Estimated Primary Completion Date : December 17, 2019
Estimated Study Completion Date : December 17, 2020


Arm Intervention/treatment
Experimental: Treatment (SVN53-67/M57-KLH peptide vaccine, octreotide)
Patients receive a SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC on day 0. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Patients also receive octreotide acetate IM on day 0. Cycles of octreotide acetate repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain free of tumor progression at 6 months and do not develop any regimen-related toxicity or serious adverse events will be eligible to receive additional doses of the vaccine and sargramostim every 3 months, for up to 1 year from the start of treatment.
Biological: Incomplete Freund's Adjuvant
Given SC
Other Names:
  • Freund's Incomplete Adjuvant
  • IFA
  • ISA-51
  • Montanide ISA 51
  • Montanide ISA-51

Drug: Octreotide Acetate
Given IM
Other Names:
  • D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt)
  • Longastatin
  • Longastatina
  • Samilstin
  • Sandostatin
  • Sandostatin Lar Depot
  • Sandostatina
  • Sandostatine
  • SMS 201-995
  • SMS 201-995 AC

Biological: Sargramostim
Given SC
Other Names:
  • 23-L-Leucinecolony-Stimulating Factor 2
  • DRG-0012
  • Leukine
  • Prokine
  • rhu GM-CFS
  • Sagramostim
  • Sargramostatin

Biological: SVN53-67/M57-KLH Peptide Vaccine
Given SC




Primary Outcome Measures :
  1. Incidence of adverse events of SVN53-67/M57-KLH peptide vaccine in combination with octreotide acetate in patients with neuroendocrine tumors [ Time Frame: Up to 15 months ]
    Will be assessed with National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Will consider a toxicity to be an adverse event that is possibly, probably or definitely related to treatment. The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category and grade. Will be quantified using the observed rates of the adverse events, serious adverse events (SAE) and regimen limiting toxicities. Toxicity rates will be described using upper 1-sided 95% Jeffreys binomial confidence intervals.


Secondary Outcome Measures :
  1. Immunogenicity of SVN53-67/M57-KLH peptide vaccine [ Time Frame: Baseline up to 15 months ]
    Survivin-specific CD8+ responses will be measured individually at baseline, 12 weeks and end of-study. These measures will be summarized by descriptive statistics (means, medians, quartiles, etc.). Confidence intervals will be constructed for the median and the mean. Exploratory graphical analysis will be used to discover associations among variables.

  2. Immunogenicity of SVN53-67/M57-KLH peptide vaccine [ Time Frame: Baseline up to 15 months ]
    Anti-survivin antibody (humoral) responses will be measured individually at baseline, 12 weeks and end of-study. These measures will be summarized by descriptive statistics (means, medians, quartiles, etc.). Confidence intervals will be constructed for the median and the mean. Exploratory graphical analysis will be used to discover associations among variables.

  3. Rate of progression [ Time Frame: Up to 15 months ]
    Will be based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 on computed tomography scan and comparison rate prior to start of treatment.

  4. Clinical benefit [ Time Frame: Up to 12 months ]
    Will be assessed with RECIST v1.1. Clinical Benefit (CB) is defined as number of patients having best overall response as complete response (CR), partial response (PR) or stable disease (SD). The estimated distribution of CB will be plotted using Kaplan Meier curves and reported with median survival and 95% confidence intervals if available.

  5. Time to progression (TTP) [ Time Frame: From enrollment to first documented progression per RECISTv1.1, assessed up to 15 months ]
    The TTP of each patient will be compared to TTP prior to study entry. The analysis will be descriptive and reported separately for each patient.

  6. Overall response rate (ORR) [ Time Frame: Up to 15 months ]
    Measured by RECIST v1.1.

  7. Duration of response (DOR) [ Time Frame: Up to 15 months ]
    Measured by RECIST v1.1.


Other Outcome Measures:
  1. Serum levels of chromogranin A, serotonin and 5-HIAA [ Time Frame: Baseline up to 15 months ]
    Exploratory graphical analysis will be used to discover associations among variables.

  2. Serum levels of serotonin and 5-HIAA [ Time Frame: Baseline up to 15 months ]
    Exploratory graphical analysis will be used to discover associations among variables

  3. Serum levels of 5-HIAA [ Time Frame: Baseline up to 15 months ]
    Exploratory graphical analysis will be used to discover associations among variables



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have a Karnofsky performance status >= 70 or Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (i.e. the patient must be able to care for himself/ herself with occasional help from others).
  • Pathologically confirmed diagnosis of neuroendocrine tumor of gastrointestinal, pancreatic or lung origin.
  • Previous treatment with somatostatin analogues and documented progression within last 6 months on 2 successive computed tomography (CT) scans, at least 4 weeks apart, as defined by RECIST v1.1 while on somatostatin analogue.
  • Availability of adequate tissue from previous biopsy of neuroendocrine tumor to test for survivin expression by tumor cells using immunohistochemistry.
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (obtained within 14 days prior to enrollment).
  • Platelets >= 100 x 10^9/L (obtained within 14 days prior to enrollment).
  • Hemoglobin (Hgb) > 9.0 g/dL (obtained within 14 days prior to enrollment).
  • Plasma total bilirubin: =< 1.5 x upper limit of normal (ULN) (obtained within 14 days prior to enrollment).
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 4.0 x ULN (obtained within 14 days prior to enrollment).
  • Patients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet the following criteria:

    • No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices, which carries a significant risk of bleeding in investigator?s opinion).
  • Creatinine =< 1.8 mg/dl (obtained within 14 days of enrollment).
  • Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and, have a negative pregnancy test prior to starting study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion Criteria:

  • The patient must not have received any immunotherapy for any malignancy.
  • Patients with serious concurrent infection or medical illness, which in the treating physicians? opinion would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety.
  • Patients who are pregnant or breast-feeding.
  • Patients with a concurrent or prior malignancy are ineligible unless they are patients with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin. Patients who have been free of disease (any prior malignancy) for at least 3 years are eligible for this study.
  • Known history of an autoimmune disorder.
  • Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS) related illness or other serious medical illness.
  • Previous local therapy (e.g. chemo-embolization, bland, or radio-embolization) is allowed if completed > 6 weeks prior to randomization. For subjects who received local therapy prior to randomization, there must be documented growth of measurable disease within the embolization field prior to study.
  • Unwilling or unable to follow protocol requirements.
  • Systemic corticosteroid therapy > 2 mg of dexamethasone or equivalent per day at study entry.
  • Any condition which in the investigator?s opinion deems the participant an unsuitable candidate to receive study drug.
  • Received an investigational agent within 30 days prior to enrollment.
  • Clinically significant cardiac arrhythmia, bradycardia, tachycardia that would compromise patient safety or the outcome of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03879694


Locations
Layout table for location information
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Renuka V. Iyer    716-845-2300    Renuka.Iyer@roswellpark.org   
Principal Investigator: Renuka V. Iyer         
Sponsors and Collaborators
Roswell Park Cancer Institute
NeuroEndocrine Tumor Research Foundation (NETRF)
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Renuka V Iyer Roswell Park Cancer Institute

Layout table for additonal information
Responsible Party: Roswell Park Cancer Institute
ClinicalTrials.gov Identifier: NCT03879694     History of Changes
Other Study ID Numbers: I 79518
NCI-2019-00827 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
I 79518 ( Other Identifier: Roswell Park Cancer Institute )
P30CA016056 ( U.S. NIH Grant/Contract )
First Posted: March 19, 2019    Key Record Dates
Last Update Posted: June 21, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Carcinoid Tumor
Neoplasms
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Glandular and Epithelial
Adenocarcinoma
Carcinoma
Octreotide
Vaccines
Sargramostim
Freund's Adjuvant
Immunologic Factors
Physiological Effects of Drugs
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Adjuvants, Immunologic